598 related articles for article (PubMed ID: 26946217)
21. Predictive value of PD-L1 expression in response to immune checkpoint inhibitors for esophageal cancer treatment: A systematic review and meta-analysis.
Noori M; Yousefi AM; Zali MR; Bashash D
Front Oncol; 2022; 12():1021859. PubMed ID: 36591463
[TBL] [Abstract][Full Text] [Related]
22. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis.
Ciccarese C; Iacovelli R; Bria E; Palazzo A; Maiorano BA; Mosillo C; Carbone C; Piro G; Tortora G
J Immunother; 2020 Apr; 43(3):95-103. PubMed ID: 32080018
[TBL] [Abstract][Full Text] [Related]
23. A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes.
Gyawali B; Hey SP; Kesselheim AS
JAMA Netw Open; 2018 Jun; 1(2):e180416. PubMed ID: 30646078
[TBL] [Abstract][Full Text] [Related]
24. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
[TBL] [Abstract][Full Text] [Related]
25. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis.
Yang F; Markovic SN; Molina JR; Halfdanarson TR; Pagliaro LC; Chintakuntlawar AV; Li R; Wei J; Wang L; Liu B; Nowakowski GS; Wang ML; Wang Y
JAMA Netw Open; 2020 Aug; 3(8):e2012534. PubMed ID: 32766800
[TBL] [Abstract][Full Text] [Related]
26. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
27. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?
Wu Q; Luo S; Xie X
J Immunother; 2022 Sep; 45(7):307-320. PubMed ID: 35674663
[TBL] [Abstract][Full Text] [Related]
28. Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis.
Li F; Zhai S; Lv Z; Yuan L; Wang S; Jin D; Yi H; Fu L; Mao Y
Front Oncol; 2022; 12():968517. PubMed ID: 36439448
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitor doublets: Are they beneficial for older patients? A systematic review and meta-analysis.
Dottorini L; Ghidini A; Deda R; Sarno I; Cavallone M; Luciani A; Petrelli F
J Geriatr Oncol; 2024 May; 15(4):101741. PubMed ID: 38462434
[TBL] [Abstract][Full Text] [Related]
30. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Dai L; Jin B; Liu T; Chen J; Li G; Dang J
EClinicalMedicine; 2021 Aug; 38():100990. PubMed ID: 34505024
[TBL] [Abstract][Full Text] [Related]
31. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
32. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F; Pala L; Bagnardi V; De Pas T; Martinetti M; Viale G; Gelber RD; Goldhirsch A
Lancet Oncol; 2018 Jun; 19(6):737-746. PubMed ID: 29778737
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Kim JH; Kim HS; Kim BJ
Oncotarget; 2017 Nov; 8(54):93149-93155. PubMed ID: 29190984
[TBL] [Abstract][Full Text] [Related]
34. Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials.
Grassadonia A; Sperduti I; Vici P; Iezzi L; Brocco D; Gamucci T; Pizzuti L; Maugeri-Saccà M; Marchetti P; Cognetti G; De Tursi M; Natoli C; Barba M; Tinari N
J Clin Med; 2018 Dec; 7(12):. PubMed ID: 30545122
[TBL] [Abstract][Full Text] [Related]
35. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
Wu Q; Liu J; Wu S; Xie X
Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of immune checkpoint inhibitors in elderly patients aged ≥ 75 years.
Petrelli F; Inno A; Ghidini A; Gori S; Bersanelli M
Cancer Immunol Immunother; 2021 Jun; 70(6):1777-1780. PubMed ID: 33170348
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis.
Tan Q; Liu S; Liang C; Han X; Shi Y
Thorac Cancer; 2018 Oct; 9(10):1220-1230. PubMed ID: 30151899
[TBL] [Abstract][Full Text] [Related]
38. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
Front Oncol; 2022; 12():753234. PubMed ID: 35280736
[TBL] [Abstract][Full Text] [Related]
39. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
40. Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy.
Pradeep J; Win TT; Aye SN; Sreeramareddy CT
J Cancer; 2022; 13(10):3091-3102. PubMed ID: 36046644
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]